Amgen Launched UPLIZNA for Myasthenia Gravis in Canada
The drug is now available for adult patients as an add-on treatment for generalized myasthenia gravis.
Updated on Oct. 13, 2026 in Alzheimer’s
Live Poll
Do you feel new treatment options are making it easier to manage long-term chronic conditions?
Amgen Canada has released UPLIZNA for prescription as an add-on treatment for adult patients suffering from generalized myasthenia gravis. The medication is intended for those with anti-AChR+ and anti-MuSK+ forms of the disease.
Why it matters
The treatment aims to provide long-term disease control and potentially reduce a patient's reliance on steroids. It represents a new therapeutic option for individuals living with this chronic autoimmune condition.
UPLIZNA is a humanized monoclonal antibody that targets CD19+ B-cells to manage disease symptoms. Clinical data shows that 87.4 percent of patients on the therapy successfully reduced steroid doses to 5mg, compared to 84.6 percent in the placebo group.
The players
Amgen Canada
This subsidiary of the global biotechnology firm is based in Mississauga, Ontario, and operates research facilities in Burnaby, British Columbia.
The details
Patients receive two initial loading doses, followed by maintenance doses administered every six months. The medication is specifically approved for adults with detectable anti-AChR or anti-MuSK antibodies.
Timeline
UPLIZNA was approved for IgG4-related disease in 2025.
Steroid tapering began during Week 4 of the MINT trial.
Steroid dose reduction outcomes were measured at Week 26 of the trial.
UPLIZNA became available for prescription in Canada on October 13, 2026.
Health Landscape
This release follows the 2025 approval of UPLIZNA for Immunoglobulin G4-related disease in Canada. It marks an expansion of the drug's therapeutic application, leveraging the same monoclonal antibody platform to address additional autoimmune conditions.
Patients now have access to a new add-on therapy that targets CD19+ B-cells to help manage symptoms. This treatment option may allow adults with generalized myasthenia gravis to reduce their reliance on steroids.
The takeaway
This treatment offers a new biannual dosing schedule that may simplify long-term management for eligible patients. Individuals should consult their specialist to determine if this monoclonal antibody is a suitable addition to their current therapy.
Further reading
For additional context on chronic disease management, visit the Alzheimer’s section.
Source note: This article includes information reported by Chatham Daily News.
Live Poll
Do you feel new treatment options are making it easier to manage long-term chronic conditions?
